Robert Michael Fairchild, MD
Rheumatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fairchild’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A126504 · Current
Licensed to practise in California · since 2013 · expires 2026-12-31 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$36,603
Medicare paid this office $36,603 for 216 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 130 | $14,200 | $82 |
| Short return visit (20+ min) | 39 | $4,088 | $77 |
| Return visit (30+ min) | 34 | $3,694 | $97 |
| New patient visit (60+ min) | 11 | $1,640 | $149 |
| Complete ultrasound scan of joint | 25 | $1,051 | $36 |
See all 11 services
| Return visit (30+ min) | 130 | $14,200 | $82 |
| Short return visit (20+ min) | 39 | $4,088 | $77 |
| Return visit (30+ min) | 34 | $3,694 | $97 |
| New patient visit (60+ min) | 11 | $1,640 | $149 |
| Complete ultrasound scan of joint | 25 | $1,051 | $36 |
| Aspiration and/or injection of fluid from small joint using ultrasound guidance | 13 | $933 | $52 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 39 | $794 | $14 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 11 | $788 | $49 |
| Aspiration and/or injection of fluid from small joint | 15 | $568 | $35 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 18 | $557 | $28 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 14 | $255 | $15 |
Who their Medicare patients are
216 Original Medicare patients in 2024. Average age 72 · Under 65 14% · 85 and older 10% · Women 72% · Also on Medicaid 33% · Health risk score 1.76. Above the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 72% · Diabetes 33% · Coronary heart disease 30% · Chronic kidney disease 28% · Depression 27% · Cancer 19% · Heart failure 18% · Atrial fibrillation 15% · COPD 14% · Stroke 11% · Dementia 8%.
The office billed $177,930, Medicare allowed $49,595 and paid $36,603; for 543 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 216 | 543 | 72 | 1.76 | $177,930 | $36,603 |
| 2023 | 168 | 351 | 70 | 1.57 | $118,501 | $23,025 |
| 2022 | 201 | 464 | 70 | 1.66 | $160,735 | $29,470 |
| 2021 | 202 | 485 | 70 | 1.52 | $158,158 | $29,278 |
| 2020 | 204 | 502 | 70 | 1.67 | $142,905 | $29,314 |
| 2019 | 245 | 648 | 69 | 1.84 | $136,175 | $41,420 |
| 2018 | 219 | 524 | 68 | 1.86 | $113,597 | $37,569 |
| 2017 | 95 | 179 | 68 | 1.38 | $51,767 | $14,642 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 116 | $12,429 | $86 |
| Short return visit (20+ min) | 40 | $2,597 | $52 |
| Complete ultrasound scan of joint | 31 | $1,574 | $40 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 17 | $521 | $29 |
2022: 9 services
| Return visit (30+ min) | 140 | $14,968 | $84 |
| Short return visit (20+ min) | 45 | $3,386 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,041 | $66 |
| Complete ultrasound scan of joint | 59 | $1,995 | $27 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,513 | $126 |
| Injection into tendon or ligament | 13 | $620 | $41 |
| Aspiration and/or injection of fluid from small joint | 11 | $438 | $34 |
| Aspiration and/or injection of fluid from large joint | 11 | $393 | $36 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 14 | $344 | $20 |
2021: 6 services
| Return visit (30+ min) | 136 | $14,169 | $86 |
| Short return visit (20+ min) | 59 | $4,066 | $51 |
| Complete ultrasound scan of joint | 63 | $2,616 | $28 |
| New patient visit (45+ min) | 12 | $1,580 | $132 |
| Aspiration and/or injection of fluid from small joint | 18 | $779 | $31 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 11 | $242 | $22 |
2020: 7 services
| Return visit (30+ min) | 143 | $13,393 | $67 |
| New patient visit (60+ min) | 21 | $3,099 | $148 |
| Complete ultrasound scan of joint | 54 | $2,200 | $29 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,397 | $74 |
| Short return visit (20+ min) | 26 | $1,147 | $42 |
| Return visit (30+ min) | 21 | $1,131 | $47 |
| Aspiration and/or injection of fluid from small joint | 15 | $561 | $28 |
2019: 10 services
| Return visit (30+ min) | 151 | $16,073 | $66 |
| New patient visit (60+ min) | 52 | $7,118 | $137 |
| Complete ultrasound scan of joint | 85 | $3,099 | $27 |
| Return visit (30+ min) | 25 | $2,653 | $76 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,951 | $122 |
| New patient visit (60+ min) | 13 | $1,938 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,746 | $58 |
| Aspiration and/or injection of fluid from large joint | 18 | $947 | $41 |
| Aspiration and/or injection of fluid from small joint | 14 | $643 | $34 |
| Complete ultrasound scan of joint | 12 | $497 | $28 |
2018: 10 services
| Return visit (30+ min) | 88 | $8,018 | $64 |
| New patient visit (60+ min) | 56 | $8,001 | $143 |
| Long return visit (40+ min) | 28 | $3,591 | $97 |
| New patient visit (45+ min) | 26 | $2,699 | $104 |
| New patient visit (60+ min) | 15 | $2,659 | $177 |
| Return visit (30+ min) | 22 | $2,148 | $77 |
| Complete ultrasound scan of joint | 62 | $1,840 | $27 |
| Aspiration and/or injection of fluid from large joint | 13 | $664 | $44 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 18 | $368 | $17 |
| Complete ultrasound scan of joint | 13 | $336 | $24 |
2017: 5 services
| New patient visit (45+ min) | 21 | $2,426 | $116 |
| Return visit (30+ min) | 25 | $2,257 | $68 |
| New patient visit (45+ min) | 14 | $2,128 | $152 |
| Complete ultrasound scan of joint | 14 | $373 | $27 |
| Complete ultrasound scan of joint | 12 | $345 | $29 |
Medicaid work
$2,181 in 2024
Medicaid paid $2,181 for 29 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 29 | $2,181 |
| 2024 | 29 | 1 | 15 | $2,181 |
| 2023 | 27 | 1 | 13 | $1,035 |
| 2022 | 44 | 1 | 16 | $1,351 |
| 2021 | 27 | 1 | 13 | $1,050 |
| 2020 | 38 | 1 | 13 | $1,695 |
| 2019 | 139 | 1 | 18 | $5,308 |
| 2018 | 26 | 1 | 14 | $1,203 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 27 | $1,035 |
2022
| Return visit (30+ min) | 44 | $1,351 |
2021
| Return visit (30+ min) | 27 | $1,050 |
2020
| Return visit (30+ min) | 38 | $1,695 |
2019
| Return visit (30+ min) | 139 | $5,308 |
2018
| Return visit (30+ min) | 26 | $1,203 |
Drugs they prescribed that Part D paid
$917,094
Pharmacies billed $917,094 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 462) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
305 generic and 157 brand-name prescriptions · $917,094 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira | 40 | $278,594 | $6,965 |
| Xeljanz Xr | 35 | $208,550 | $5,959 |
| Humira(Cf) | 11 | $86,893 | $7,899 |
| Humira | 12 | $71,275 | $5,940 |
| Methotrexate | 86 | $2,106 | $24 |
See all 12 drugs
| Humira | 40 | $278,594 | $6,965 |
| Xeljanz Xr | 35 | $208,550 | $5,959 |
| Humira(Cf) | 11 | $86,893 | $7,899 |
| Humira | 12 | $71,275 | $5,940 |
| Methotrexate | 86 | $2,106 | $24 |
| Leflunomide | 38 | $1,817 | $48 |
| Hydroxychloroquine Sulfate | 31 | $1,497 | $48 |
| Sulfasalazine | 22 | $1,114 | $51 |
| Prednisone | 53 | $628 | $12 |
| Folic Acid | 24 | $306 | $13 |
| Allopurinol | 16 | $236 | $15 |
| Meloxicam | 12 | $127 | $11 |
Year by year
| 2024 | 462 | 69 | 0% (0) | 34% | $917,094 |
| 2023 | 390 | 64 | 0% (0) | 33% | $879,408 |
| 2022 | 398 | 58 | 0% (0) | None | $614,297 |
| 2021 | 396 | 62 | 0% (0) | 24% | $540,181 |
| 2020 | 535 | 90 | None | 27% | $553,534 |
| 2019 | 579 | 104 | 0% (0) | 22% | $414,567 |
| 2018 | 495 | 90 | None | 27% | $344,487 |
| 2017 | 125 | 39 | 0% (0) | 24% | $72,924 |
| 2015 | 12 | None | None | None | $14,249 |
| 2013 | 15 | None | None | 0% | $4,159 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Humira | 49 | $358,938 | $7,325 |
| Xeljanz Xr | 28 | $164,379 | $5,871 |
| Humira(Cf) | 13 | $98,138 | $7,549 |
| Humira | 12 | $80,995 | $6,750 |
| Hydroxychloroquine Sulfate | 36 | $2,998 | $83 |
| Leflunomide | 24 | $2,165 | $90 |
| Methotrexate | 67 | $2,122 | $32 |
| Prednisone | 50 | $1,070 | $21 |
| Sulfasalazine | 18 | $949 | $53 |
| Allopurinol | 11 | $99 | $9 |
| Folic Acid | 19 | $77 | $4 |
2022: 10 drugs
| Humira | 35 | $231,034 | $6,601 |
| Xeljanz Xr | 20 | $106,325 | $5,316 |
| Humira | 12 | $56,150 | $4,679 |
| Leflunomide | 19 | $4,180 | $220 |
| Methotrexate | 63 | $2,678 | $43 |
| Hydroxychloroquine Sulfate | 41 | $2,082 | $51 |
| Azathioprine | 12 | $1,776 | $148 |
| Prednisone | 61 | $1,376 | $23 |
| Sulfasalazine | 23 | $938 | $41 |
| Allopurinol | 25 | $274 | $11 |
2021: 11 drugs
| Humira | 31 | $225,037 | $7,259 |
| Xeljanz Xr | 32 | $166,442 | $5,201 |
| Cosentyx Pen (2 Pens) | 13 | $74,838 | $5,757 |
| Leflunomide | 17 | $3,728 | $219 |
| Methotrexate | 73 | $3,581 | $49 |
| Hydroxychloroquine Sulfate | 50 | $3,452 | $69 |
| Colchicine | 11 | $2,167 | $197 |
| Sulfasalazine | 21 | $1,189 | $57 |
| Prednisone | 45 | $1,065 | $24 |
| Allopurinol | 35 | $437 | $12 |
| Alendronate | 14 | $66 | $5 |
2020: 11 drugs
| Xeljanz Xr | 33 | $160,534 | $4,865 |
| Humira | 20 | $142,570 | $7,128 |
| Hydroxychloroquine Sulfate | 60 | $6,979 | $116 |
| Leflunomide | 31 | $4,501 | $145 |
| Methotrexate | 75 | $3,845 | $51 |
| Febuxostat | 11 | $2,839 | $258 |
| Sulfasalazine | 24 | $1,464 | $61 |
| Prednisone | 75 | $984 | $13 |
| Allopurinol | 49 | $693 | $14 |
| Diclofenac | 30 | $682 | $23 |
| Alendronate | 14 | $88 | $6 |
2019: 13 drugs
| Humira | 19 | $117,992 | $6,210 |
| Xeljanz Xr | 21 | $95,164 | $4,532 |
| Colcrys | 22 | $10,050 | $457 |
| Hydroxychloroquine Sulfate | 48 | $6,924 | $144 |
| Methotrexate | 92 | $5,009 | $54 |
| Leflunomide | 12 | $3,773 | $314 |
| Prednisone | 97 | $1,244 | $13 |
| Diclofenac | 38 | $1,017 | $27 |
| Sulfasalazine | 19 | $839 | $44 |
| Allopurinol | 42 | $788 | $19 |
| Alendronate | 12 | $169 | $14 |
| Gabapentin | 12 | $165 | $14 |
| Meloxicam | 11 | $38 | $3 |
2018: 10 drugs
| Humira | 33 | $198,929 | $6,028 |
| Hydroxychloroquine Sulfate | 47 | $6,954 | $148 |
| Colchicine | 17 | $5,856 | $344 |
| Methotrexate | 94 | $3,627 | $39 |
| Prednisone | 70 | $1,085 | $15 |
| Allopurinol | 34 | $1,053 | $31 |
| Sulfasalazine | 15 | $631 | $42 |
| Alendronate | 16 | $196 | $12 |
| Gabapentin | 14 | $122 | $9 |
| Meloxicam | 14 | $45 | $3 |
2017: 2 drugs
| Methotrexate | 24 | $1,019 | $42 |
| Prednisone | 17 | $366 | $22 |
Money from drug and device companies
$148 in 2024
| 2024 | 2 | 2 | None | $148 |
| 2021 | 1 | 1 | None | $116 |
| 2019 | 1 | 1 | None | $115 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | None | $123 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $25 | 1 payment
|
See all 2 published payments
| Novartis Pharmaceuticals | Meals · 2024-05-18 | Cosentyx | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2024-05-16 | None | $123 |
See earlier years (2021, 2019)
2021: $116
| Gilead Sciences | None | $116 | 1 payment
|
2019: $115
| Boehringer Ingelheim Pharmaceuticals | None | $115 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Boehringer Ingelheim International GmbH · Screening for Ild in Patients With Ra · 2024 | Their institution | $106,662 |
| Boehringer Ingelheim International GmbH · A Prospective, Multi-National, Cross-Sectional Study on A Risk-Factor Guided Approach To Interstitial Lung Disease Screening in Patients With Rheumatoid Arthritis at Higher Risk for Ild Using High Resolution Computed Tomography · 2025 | Their institution | $80,425 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1255607214
- Licence
- CA A126504California A126504: Current · expires 2026-12-31
- Trained
- Columbia University College of Physicians and Surgeons, 2012
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2012-03-23
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.